of the North Caucasus
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137
русский
english
Site search
Correspondence address
310 Mira Street, Stavropol, Russia, 355017
Tel
+7 865 2352511, +7 865 2353229.
E-mail
medvestnik@stgmu.ru
The journal is included into The list of leading scientific periodicals.
The journal is included into VINITI database and is registered in Electronic scientific library.
The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.
Amyloid cardiopathy: clinical observation
[Notes from practice]
Yulia Shulpekova; Sergey Baranov; Vladimir Nechayev; Ivan Vladimirovich Supryaga; Irina Ivanovna Yakushina; Amina Sultanovna Garayeva;
Restrictive amyloid cardiopathy (AL-amyloidosis) is a rare disease with an unfavorable prognosis. General practitioners and practicing cardiologists are not familiar enough with this nosological form. Diagnostic keys are hypodiastolic heart failure, severe arrhythmias, systemic lesions (involvement of kidneys, skin, peripheral nerves, lungs and endocrine glands). The diagnosis should be verified based on the results of magnetic resonance imaging and morphological examination of the heart. In thioflavin-stained T preparations, a specific green glow is detected during luminescence microscopy. The prognosis for life is unfavorable: death occurs from non-curable arrhythmias and heart failure.
References:
1. Kristen A. V. Amyloid cardiomyopathy. Herz. 2020;2(27). https://doi.org/10.1007/s00059-020-04904-4
2. Povar-Echeverría M., Auquilla-Clavijo P. E., Povar-Marco B. J., Moreno-Esteban E. M., Figueras-Villalba M. P. Cardiac amyloidosis: a review of a series of cases. Arch. Cardiol. Mex. 2020;90(3):259-265. https://doi.org/10.24875/ACM.19000238
3. Garcia-Pavia P., Domínguez F., Gonzalez-Lopez E. Transthyretin amyloid cardiomyopathy. Med. Clin. (Barc). 2021;156(3):126-134. https://doi.org/10.1016/j.medcli.2020.06.064
4. Agha A. M., Parwani P., Guha A., Durand J. B., Iliescu C. A. [et al.]. Role of cardiovascular imaging for the diagnosis and prognosis of cardiac amyloidosis. Open Heart. 2018;5(2):e000881. https://doi.org/10.1136/openhrt-2018-000881
5. Blagova O. V., Nedostup A. V., Sedov V. P., Kogan E. A., Pasha S. P. [et al.]. Clinical masks of amyloidosis with the heart involvement: modern diagnostic issues. Rossijskij kardiologicheskij zhurnal. – Russian Journal of Сardiology. 2017;2(142):68-79. (In Russ.). https://doi.org/10.15829/1560-4071-2017-2-68-79
6. Oda S., Kawano Y., Okuno Y., Utsunomiya D., Nakaura T. [et al.]. Base-to-apex gradient pattern of cardiac impairment identified on myocardial T1 mapping in cardiac amyloidosis. Radiol. Case Rep. 2018;14(1):72-74. https://doi.org/10.1016/j.radcr.2018.09.025
7. Lilleness B., Ruberg F. L., Mussinelli R., Doros G., Sanchorawala V. Development and validation of a survival staging system incorporating BNP in patients with light chain (AL) amyloidosis. Blood. 2019;133(3):215-223. https://doi.org/10.1182/blood-2018-06-858951
8. Aimo A., Buda G., Fontana M., Barison A., Vergaro G. [et al.]. Therapies for cardiac light chain amyloidosis: an update. Int. J. Cardiol. 2018;271:152-160. https://doi.org/10.1016/j.ijcard.2018.05.018
9. Di Giovanni B., Gustafson D., Adamson M. B., Delgado D. H. Hiding in plain sight: cardiac amyloidosis, an emerging epidemic. Can. J. Cardiol. 2020;36(3):373-383. https://doi.org/10.1016/j.cjca.2019.12.015
10. Ryšavá R. AL amyloidosis: advances in diagnostics and treatment. Nephrol. Dial. Transplant. 2019;34(9):1460-1466. https://doi.org/10.1093/ndt/gfy291
11. Tuzovic M., Yang E. H., Baas A. S., Depasquale E. C., Deng M. C. [et al.]. Cardiac amyloidosis: diagnosis and treatment strategies. Curr. Oncol. Rep. 2017;19(7):46. https://doi.org/10.1007/s11912-017-0607-4
12. Palladini G., Milani P., Merlini G. Management of AL amyloidosis in 2020. Blood. 2020;136(23):2620-2627. https://doi.org/10.1182/blood.2020006913
13. Garcia-Pavia P., Rapezzi C., Adler Y., Arad M., Basso C. [et al.]. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 2021;42(16):1554-1568. https://doi.org/10.1093/eurheartj/ehab072
Keywords: amyloid cardiopathy, restrictive cardiopathy, AL-amyloidosis, diastolic heart failure, periorbital purpura
Founders:
Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy